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Fibroblast growth factorr extracellular matrix proteins: tenascin-C, X, R and W. The four members of the
family have strikingly diverse patterns of expression during development and in the adult organism
indicating independent mechanisms of regulation. In this review we illustrate that there are two types of
tenascins, those that are signiﬁcantly regulated by the tissue microenvironment (tenascin-C and tenascin-
W), and those that have stabile, restricted expression patterns (tenascin-R and tenascin-X). We summarize
what is known about the regulation of tenascin expression by transforming growth factor betas, ﬁbroblast
growth factors, platelet derived growth factors, as well as pro- and anti-inﬂammatory cytokines or hormones
that either induce or inhibit expression of tenascins.
© 2009 Elsevier B.V. All rights reserved.1. IntroductionTenascins are a family of four multimeric extracellular matrix
(ECM) glycoproteins: tenascin-C, X, R and W [1]. The best described
member of the family is tenascin-C, which is found in the embryo near
migrating cells, at sites of epithelial–mesenchymal interactions and
branching morphogenesis, and in developing connective tissue
including bone, cartilage and tendons. Tenascin-C persists in some
connective tissue in the adult, and also appears in the stroma of many
tumors and at sites of tissue repair and regeneration (for reviews see
[2–4]). Tenascin-X is primarily expressed in loose connective tissue
such as dermis, epimysium and blood vessels both during develop-
ment and in the adult; mutations in tenascin-X can lead to a type of
Ehlers–Danlos Syndrome (for review see [5]). In contrast, the patterns
of tenascin-R and tenascin-W expression in normal developing and
adult tissues are considerably more restricted. Tenascin-R is concen-
trated in the central and peripheral nervous system (e.g. [6]), and
tenascin-W is found primarily in bone (e.g. [7]). Like tenascin-C,
tenascin-W is also a prominent component of the stroma of certain
tumors [8–10]. The primary sites of tenascin expression are summar-
ized in Table 1.
Diverse functional roles have been assigned to tenascins during
development and disease. When used as a substratum in tissue
culture, some tenascins inhibit the spreading of cells and the
formation of large focal adhesions. Similarly, tenascins added to the
medium of cells cultured on adhesive ECM can cause the cells toll rights reserved.become more rounded or for growth cones to collapse (e.g., for
tenascin-C see [11]; for tenascin-R see [12]; for tenascin-X see [13]).
This is often, but not always, accompanied by an increase in rates of
motility, invasive behavior and proliferation (for reviews see [4,14]).
Tenascin-W seems to have similar properties. For example, tenascin-
W added to the medium of primary cultures of osteoblasts on
ﬁbronectin leads to cell rounding [15] and the migration of a
mammary tumor-derived cell line across a ﬁlter in a Boyden chamber
assay is stimulated by tenascin-W [8]. An attractive model to explain
some of these observations, at least for tenascin-C, comes from studies
of tenascin-C/ﬁbronectin interactions. When cells are cultured on a
combination of tenascin-C and ﬁbronectin, as opposed to ﬁbronectin
alone, there is a reduction in the expression or activity of FAK, RhoA
and tropomyosin I [16–18]. This appears to be mediated by tenascin-C
inhibiting interactions between syndecan-4 and ﬁbronectin [19,20],
which in turn inhibits the recruitment of syndecan-4 to the focal
adhesion complex. This limits the size of the focal adhesion and alters
integrin signaling. Associatedwith this is an increase in the expression
of endothelin receptor A, which is correlated with an inhibition of
focal adhesion kinase and a loss of function of RhoA, all of which can
contribute to tumorigenesis [21].
Since it was ﬁrst observed in tumor stroma over two decades ago
[22] considerable research has been directed toward understanding
the role of tenascin-C in cancer (for review see [23]). More recently, it
was observed that tenascin-W is also found in the stroma of murine
[8] and human [9,10] breast cancers. Given the effects of tenascin-C
and tenascin-W on cells in vitro cited above, it is likely that these
proteins can contribute directly to the growth and metastasis of at
least some tumors. However, care must be taken not to generalize
roles for all tenascins in cancer. For example, tenascin-R is expressed
Table 1
Summary of tenascin expression and regulation
Examples of prominent expressiona Examples of regulationb [Ref.]
Tenascin-C Organogenesis TGFβ1 [27–31,33,34]
Dense connective tissue FGF1 [49]
Smooth muscle FGF2 [28,46–50]
Inﬂammation FGF4 [49]
Cancer stroma PDGF [55]
TNFα [59–61]
Notch [77]
Downregulation by miRNAs [78]
Mechanical strain [76,83]
Tenascin-W Bone BMP2 [7,8]
Cancer stroma TNFα [8]
Tenascin-X Loose connective tissue BDNF [70]
Endothelial cells No effect seen with EGF, bFGF, TGFβ1, PDGF, and TNFα [69]
Tenascin-R Central and peripheral nervous system NGFc [68]
a See text for references to reviews of expression patterns.
b Upregulation unless otherwise noted.
c May be related to the differentiation of a cell line.
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[24], and melanoma cells are more invasive in the ECM of tenascin-X
knockout mice than in controls [25].
Clearly tenascin gene expression is tightly regulated and is
dependent on the tissue microenvironment, especially on the growth
factor milieux. This is apparent from the distinctive and often
complementary patterns of tenascin gene expression in the embryo
and from the presence or absence of tenascins in the stroma of certain
tumors. In this review we will summarize the research on the effects
of growth factors on the expression of tenascins in vitro and the
signaling pathways used to stimulate tenascin expression.
2. Regulation of tenascin-C expression by transforming growth
factor betas
Transforming growth factor betas (TGFβ) are a superfamily of
cytokines that play important roles in regulating cell differentiation
and proliferation, both during development and in pathologies (for
review see [26]). In one of the earliest studies of any tenascin, Pearson
et al. [27] showed that tenascin-C expression by chick embryo
ﬁbroblasts is upregulated four-fold by the addition of 6–20 ng/ml of
TGFβ1 to low-serum medium (see Table 1 for a summary of the
regulation of tenascin expression). Similar induction of tenascin-C
expression by low levels of TGFβ1 was reported in Swiss 3T3 cells [28]
and in various human carcinoma-derived cell lines [29] and
transformed mouse mammary epithelial cells [30]. Interestingly,
when melanoma cells are transfected with TGFβ1 and seeded into
collagen gels together with ﬁbroblasts, tenascin-C expression
increases in the ﬁbroblasts [31], suggesting that some of the
tenascin-C found in tumor stroma may be deposited by the stromal
cells under the inﬂuence of the tumor-derived microenvironment.
Tenascin-C and TGFβ1 are both found in developing connective tissue
(e.g., see [32]), so it is not surprising that explants of mouse limb bud
mesenchyme also express tenascin-C in response to TGFβs [33].
Though the most robust inductive response was seen with TGFβ1,
signiﬁcant induction was also reported with TGFβ2 and TGFβ3.
Interestingly, TGFβ1 tends to induce most strongly the expression of a
low molecular weight alternatively spliced variant of tenascin-C that
lacks the so-called ‘variable domain’. This has been reported in Swiss
3T3 cells [28] and endometrial adenocarcinoma cell lines [34]. The
functional signiﬁcance of this is unclear, but different splice variants
have been shown to be differentially expressed during development
(e.g. [35,36]) and in tumors (e.g. [37]) and to have different effects on
cell adhesion in vitro (e.g. [36]).
Correlative evidence suggests that TGFβ1 is likely to be a regulator
of tenascin-C expression in vivo as well as in vitro: the expressionpattern of TGFβ1 in the developing heart [38] and in inﬂamed joints
[39] closely matches that of tenascin-C, tenascin-C is abundant around
TGFβ1-expressing megakaryocytes in bone marrow [40], and levels of
tenascin-C and levels of TGFβ1 expression are correlated in breast
carcinomas [41] and ovarian tumors [42]. Care must be taken before
making generalizations based on the latter observations, as others
have shown no correlation between the level of tenascin-C expression
and TGFβ1 expression in gliomas [43], though both are present. This
may be explained, in part, by differences in the timing of the ﬁrst
appearance of tenascin-C and TGFβ1.
Studies with function-blocking antibodies also link TGFβ1 with the
regulation of tenascin-C expression. For example, pre- and post-
operative treatment of rats with anti-TGFβ1 inhibits the induction of
tenascin-C expression in radiation-induced wounds [44]. Others have
taken advantage of cells derived from knockout mice. Kalembeyi et al.
[45] showed that a matrix metalloprotease, MMP-9, is induced by
TGFβ1 in a tenascin-C knockout-derived tumor cell line, but that this
induction is increased in the presence of exogenous tenascin-C. Thus,
tenascin-C and TGFβ1 may act synergistically to increase the levels of
proteases in tumor stroma that can contribute to metastasis.
3. Tenascin-C expression and ﬁbroblast growth factors
Fibroblast growth factor 2 (FGF2), also known as basic ﬁbroblast
growth factor, was ﬁrst characterized as a potent promoter of
angiogenesis (for a review of the history of its discovery see [46]). It
is one of the foundingmembers of a large family of growth factors that
can regulate cell motility, proliferation, differentiation and survival.
Like TGFβ1, the pattern of expression of FGF2 is also often correlated
with the expression of tenascin-C, especially in the central nervous
system (e.g. [28]). Accordingly, FGF2 can induce the expression of
tenascin-C in astrocytes [47,48] and neuroectoderm-derived tumors
[49]. In the latter study FGF1 (aFGF) and FGF4 (K-FGF) also induced
the expression of tenascin-C. Interestingly, introduction of FGF1 into
the lateral ventricles of the rat leads to the speciﬁc induction of the
large splice variants of tenascin-C [50], and FGF2 induces the
expression of large splice variants of tenascin-C in Swiss 3T3 cells
[28]. Large splice variants of tenascin-C are often associated with
motile cells and with malignancy and poor outcome (e.g. [51–54]).
4. Platelet derived growth factors and tenascin-C expression
Platelet derived growth factors (PDGF) are dimers of A, B, C and D
subunits. Best known are PDGF-AA, PDGF-AB and PDGF-BB, which
play important rules in inﬂuencing cell proliferation and motility in a
variety of tissues. Tenascin-C and PDGFs are found together in some
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tenascin-C expression in smooth muscle cells derived from the aorta
[55]. As described above for FGF2, PDGF-BB induces primarily large
splice variants of tenascin-C; this variant may play a role in the
invasion of smooth muscles cells into the vessel wall and the
development of atherosclerotic plaque. Both PDGF receptor alpha
and tenascin-C are expressed in the developing central nervous
system by early oligodendroglia and their precursors (e.g. [56,57]).
PDGF has a potent mitogenic effect on oligodendrocyte precursor
cells; interestingly, this effect requires tenascin-C in the ECM [58],
implying that synergistic effects between growth factors and
tenascin-C may account in part for the mitogenic effects of exogenous
tenascin-C.
5. Other growth factors and other tenascins
The induction of tenascin-C in tumor stroma and at other sites of
disease progression is likely to be related to its induction by
cytokines associated with inﬂammation. For example, TNFα expres-
sion is linked to tenascin-C expression in bronchial ﬁbroblasts [59]
and cultured chondrocytes [60], and TNFα and interferon gamma
induce tenascin-C expression in bronchial epithelial cells ([61]; see
also reviews [3,23]). Anti-inﬂammatories like dexamethasone inhibit
the expression of tenascin-C in cultured human macrophages (e.g.
[62]), in the granulation tissue of healing skin wounds [63], and in
the stroma of experimentally induced murine tumors [64]. Gluco-
corticoids can reduce the expression of tenascin-C in bone marrow
[65] and in the respiratory mucosa of patients suffering from pollen-
induced asthma [66].
Tenascin-W, the most recently discovered member of the tenascin
family [67], is also expressed in tumor stroma and its expression can
also be upregulated by TNFα in vitro [8]. Nevertheless, tenascin-C and
tenascin-W are clearly regulated independently, since there are
tumors that express one of these two tenascins but not the other
[9,10]. During development, tenascin-W is most abundantly expressed
in developing bone [7,15]. Accordingly, tenascin-W expression is
increased in C2C12 cells [7] and HC11 cells [8] by bone morphogenetic
protein-2 (BMP-2), but not by TGFβ1.
Relatively little is known about the regulation of tenascin-R and
tenascin-X expression by the tissue microenvironment. Nerve growth
factor (NGF) can stimulate the expression of tenascin-R by PC12 cells
in vitro [68], but NGF stimulates the differentiation of these cells into
neuron-like cells and the induction may be indirect. The expression of
tenascin-X by ﬁbroblasts in vitro is not upregulated by a host of
growth factors, including TGFβ1, bFGF or PDGF, but like tenascin-C its
expression can be downregulated by glucocorticoids [69]. However,
there is one report that BDNF is able to upregulate tenascin-X
expression by cultured endothelial cells [70].
6. Signaling pathways used to induce tenascin expression
TGFβ1 and BMP-2, which are both members of the TGFβ super-
family, induce the expression of tenascin-C and tenascin-W, respec-
tively (see above and especially [8]). Both growth factors signal
through ligand-speciﬁc transmembrane receptor serine-threonine
kinases. Growth factor binding leads to conformational changes,
receptor phosphorylation, and the activation of the Smad complex of
transcription factors (reviewed by [71]). In contrast, osteoblast gene
expression is regulated by BMP-2 via non-canonical MAPK signaling
pathways (e.g. [72]). Scherberich et al. [8] have shown that this latter
pathway is important in the induction of tenascin-W: inhibitors of p38
and JNK reduce the endogenous expression of tenascin-W by mouse
embryo ﬁbroblasts, and p38 inhibitors block the induction of tenascin-
W expression by BMP-2 [8]. In another system, these pathways can
lead to the expression not of tenascin-W, but of tenascin-C. Mutations
in the BMP type II receptor have been linked to familial pulmonaryarterial hypertension (see review by [73]), which is characterized in
part by the extensive deposition of tenascin-C in the arterial wall (e.g.
[74]). The receptor mutation leads to a reduction in BMP-induced
Smad signaling and an increase in MAPK signaling pathways, which
leads to the induction of tenascin-C expression by vascular smooth
muscle cells [75]. The tenascin-C can contribute to the pathobiology of
the disease by increasing vascular smooth muscle cell proliferation
and survival. Regulation of tenascin-C expression can also depend on
the Rho/Rock pathway and actin dynamics ([76]; see accompanying
article by M. Chiquet on “Mechanotransduction in Fibroblasts”).
Recently, two novel mechanisms regulating tenascin-C expression
have been described. On the one hand Notch signaling was shown to
induce tenascin-C expression representing a new oncogenic pathway
active in glioblastoma [77]. On the other hand micro RNA (miRNA)-
335 was shown to downregulate tenascin-C expression and the loss of
this miRNA in metastatic breast tumors led to increased tenascin-C
expression. Restoration of miRNA-126 inhibited metastatic cell
invasion which depended on the down-regulation of tenascin-C [78].
7. Tenascin promoters and transcription factors
The distinctive differences in the expression and regulation of the
tenascins are reﬂected in features found in their promoters. For
example, the promoters of tenascin-X and tenascin-R lack TATA boxes
and in both cases transcription is initiated at multiple sites, whereas
tenascin-C is regulated by a typical TATA-box containing promoter.
Nothing is known yet about the tenascin-W promoter, which is
waiting to be identiﬁed and characterized. In the case of tenascin-R
the information for cell-type speciﬁc expression in cells of neuronal
origin is contained within 167 bp of the ﬁrst exon and contains
binding sites for a variety of transcription factors such as p53/p73, NF1
and glucocorticoid receptors [79]. However, it is not known which
factors are relevant for the expression of tenascin-R in the central
nervous system. In the case of tenascin-X it is thought that several
regions harboring binding sites for Sp1 and Sp3 are involved in its
regulation [80]. In line with the many signaling pathways able to
induce tenascin-C expression (see above and Table 1) binding sites for
the transcription factors activated by these pathways have been
identiﬁed and are functional in the promoter of tenascin-C. These
include binding sites for paired-related homeobox1 Prx1 shown to be
activated by focal adhesion kinase signaling [81], Ets factor binding
sites [82] and AP1 elements [83,84] responding to the ERK/MAPK
pathway, and Smad2/3 binding sites involved in TGFβ signaling [85].
Interestingly, many of these transcription factors can also collaborate
in the regulation of tenascin-C expression, since it was shown that
mutations of either the Smad, Ets or SP1/3 binding sites abrogated
tenascin-C promoter induction by TGFβ [85]. Recently, a transcrip-
tional repressor for tenascin-C was found. Overexpression of GATA6
reduced tenascin-C expression and inhibited IL-4 and TGFβ-induced
tenascin-C promoter activity [86]. This ubiquitously expressed
transcriptional inhibitor could be one of the factors keeping
tenascin-C expression low under normal conditions in the absence
of microenvironmental stimuli leading to tenascin-C upregulation.
8. Conclusions and future directions
This review illustrates that there are two types of tenascins: 1)
those that are signiﬁcantly regulated by the tissue microenviron-
ment (tenascin-C and tenascin-W), and 2) those that have stabile,
restricted expression patterns (tenascin-R and tenascin-X). Accord-
ingly, it is the former group that is frequently encountered in the
ECM at sites of disease or trauma, especially in the tumor stroma.
Tenascin-C and tenascin-W are also the types of tenascin with the
best documented effects on cell proliferation, differentiation and
motility, and these roles may contribute favorably, or not, to the
organism's responses to pathological events. This needs to be taken
891R.P. Tucker, R. Chiquet-Ehrismann / Biochimica et Biophysica Acta 1793 (2009) 888–892into consideration when designing therapies to combat tumor
growth and metastasis or the negative consequences of inﬂamma-
tion. Another exciting potential ﬁeld for the application of this
knowledge is the bioengineering of artiﬁcial scaffolds to promote
successful healing in response to trauma or the integration of
prosthesis into host connective tissues. These can be designed to
release the millieau of factors that optimally promotes the
expression of tenascin-C or tenascin-W, which in turn can lead to
the rapid incorporation of the appropriate host tissue in the scaffold.
Future studies should also be directed to better understand the
regulation of the other tenascins, which may play important
structural or other instructive roles in normal tissues.
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